Sajdik, Constantin
Schuster, Eva
Holzer, Barbara
Krainer, Michael
Deutschmann, Christine
Peter, Stefan
Marhold, Maximilian
Zeillinger, Robert
Obermayr, Eva http://orcid.org/0000-0001-6324-2961
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 30 June 2022
Accepted: 14 August 2022
First Online: 8 September 2022
Declarations
:
: C.D. received a travel grant from Motiva and honoraria from Roche. S.P. is an employee of ANGLE Europe Limited, Guildford, UK. ANGLE had no influence on the design of the study and on the interpretation of the results. M.M. received honoraria from Roche, Eli Lilly, Novartis, Astra Zeneca, Daiichi Sankyo, Pfizer, MSD, and Medmedia, and travel support from Amgen, Roche, Novartis, Pierre Fabre, Daiichi Sankyo, and Eisai. R.Z. and E.O. hold patents on novel markers for the detection of CTCs comprising CCNE2 and PPIC. C.S., E.S., B.H., M.K. declare no conflict of interest.
: All patients and donors had signed a written informed consent form. This study was approved by the Ethics Committee of the Medical University of Vienna, Austria (EK366/2003 and EK2266/2018).